IO Biotech Q3 2024 Earnings Report $0.86 -0.02 (-2.52%) Closing price 04/10/2025 04:00 PM EasternExtended Trading$0.85 0.00 (-0.56%) As of 06:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast IO Biotech EPS ResultsActual EPS-$0.36Consensus EPS -$0.29Beat/MissMissed by -$0.07One Year Ago EPSN/AIO Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIO Biotech Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call DateTuesday, November 12, 2024Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryIOBT ProfilePowered by Remove Ads Earnings DocumentsPress Release(8-K) IO Biotech Earnings HeadlinesIO Biotech (NASDAQ:IOBT) and Vistagen Therapeutics (NASDAQ:VTGN) Financial ContrastApril 10 at 2:23 AM | americanbankingnews.comIO Biotech (NASDAQ:IOBT) Earns "Buy" Rating from HC WainwrightApril 3, 2025 | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 11, 2025 | Porter & Company (Ad)Piper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)April 2, 2025 | markets.businessinsider.comIO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comIO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025March 18, 2025 | finance.yahoo.comSee More IO Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email. Email Address About IO BiotechIO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.View IO Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Upcoming Earnings The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)The PNC Financial Services Group (4/15/2025)ASML (4/16/2025)CSX (4/16/2025)Abbott Laboratories (4/16/2025)Kinder Morgan (4/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
